Payment overview · 2025
General Payments
$207.57
4 reported records · 3 companies
Healthcare provider profile · identity verified
Stanley Kim, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EDISON, NJ · NPI 1306850433
Verified facts
What the public records show
CMS Open Payments records show Stanley Kim, M.D. received $207.57 in general payments during 2025 across 4 reported records.
AERIN MEDICAL INC. accounted for 71.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $148.40 | 71.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.14 | 16.4% | 2 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $25.03 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.57 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $148.40 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $148.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
76 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2246 | 581 |
| Amlodipine Besylate | Amlodipine Besylate | 1502 | 385 |
| Vascepa | Icosapent Ethyl | 1218 | 173 |
| Metformin Hcl | Metformin Hcl | 1087 | 268 |
| Losartan Potassium | Losartan Potassium | 953 | 234 |
| Lidocaine | Lidocaine | 777 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 660 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 598 | 149 |
| Januvia | Sitagliptin Phosphate | 566 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 560 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 550 | 146 |
| Simvastatin | Simvastatin | 506 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 96 |
| Creon | Lipase/Protease/Amylase | 363 | 79 |
| Diclofenac Sodium | Diclofenac Sodium | 361 | 68 |
| Farxiga | Dapagliflozin Propanediol | 351 | 71 |
| Furosemide | Furosemide | 350 | 90 |
| Meloxicam | Meloxicam | 344 | 110 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 308 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 70 |
| Donepezil Hcl | Donepezil Hcl | 302 | 64 |
| Alendronate Sodium | Alendronate Sodium | 289 | 95 |
| Celecoxib | Celecoxib | 286 | 102 |
| Jardiance | Empagliflozin | 263 | 45 |
| Glimepiride | Glimepiride | 262 | 73 |
| Fenofibrate | Fenofibrate | 257 | 77 |
| Lisinopril | Lisinopril | 238 | 59 |
| Allopurinol | Allopurinol | 233 | 68 |
| Linzess | Linaclotide | 226 | 41 |
| Omeprazole | Omeprazole | 225 | 57 |
| Finasteride | Finasteride | 211 | 46 |
| Eliquis | Apixaban | 210 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 206 | 66 |
| Gabapentin | Gabapentin | 204 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 47 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 166 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 34 |
| Sertraline Hcl | Sertraline Hcl | 140 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 139 | 40 |
| Restasis | Cyclosporine | 138 | 29 |
| Alprazolam | Alprazolam | 136 | 41 |
| Fluocinonide | Fluocinonide | 136 | 53 |
| Carvedilol | Carvedilol | 130 | 30 |
| Clonazepam | Clonazepam | 123 | 29 |
| Trazodone Hcl | Trazodone Hcl | 122 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 116 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 114 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 26 |
| Ezetimibe | Ezetimibe | 105 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 104 | 31 |
| Megestrol Acetate | Megestrol Acetate | 104 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 25 |
| Calcitriol | Calcitriol | 101 | 36 |
| Famotidine | Famotidine | 101 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 101 | 81 |
| Atenolol | Atenolol | 100 | 20 |
| Ozempic | Semaglutide | 99 | 26 |
| Azelastine Hcl | Azelastine Hcl | 97 | 18 |
| Zenpep | Lipase/Protease/Amylase | 92 | 15 |
| Meclizine Hcl | Meclizine Hcl | 89 | 41 |
| Tramadol Hcl | Tramadol Hcl | 89 | 18 |
| Irbesartan | Irbesartan | 87 | 17 |
| Tradjenta | Linagliptin | 86 | 15 |
| Memantine Hcl | Memantine Hcl | 84 | 21 |
| Metformin Hcl Er | Metformin Hcl | 83 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 76 | 22 |
| Prolia | Denosumab | 76 | 42 |
| Ztlido | Lidocaine | 76 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 75 | 17 |
| Isoniazid | Isoniazid | 74 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 73 | 11 |
| Memantine Hcl Er | Memantine Hcl | 72 | 11 |
| Amoxicillin | Amoxicillin | 69 | 55 |
| Nifedipine Er | Nifedipine | 69 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 65 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | 13 |
| Cyclosporine | Cyclosporine | 62 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 60 | 16 |
| Kerendia | Finerenone | 59 | 12 |
| Montelukast Sodium | Montelukast Sodium | 56 | 19 |
| Myrbetriq | Mirabegron | 56 | 11 |
| Enalapril Maleate | Enalapril Maleate | 55 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 13 |
| Methylprednisolone | Methylprednisolone | 54 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 49 |
| Ketoconazole | Ketoconazole | 53 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 51 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 45 |
| Glipizide | Glipizide | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 45 |
| Potassium Chloride | Potassium Chloride | 47 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 46 | 13 |
| Pilocarpine Hcl | Pilocarpine Hcl | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | 12 |
| Clonidine Hcl | Clonidine Hcl | 44 | 19 |
| Velphoro | Sucroferric Oxyhydroxide | 42 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 40 | suppressed |
| Glipizide Er | Glipizide | 40 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Prednisone | Prednisone | 40 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 16 |
| Repaglinide | Repaglinide | 39 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 18 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 14 |
| Ciclopirox | Ciclopirox Olamine | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Methimazole | Methimazole | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Restasis Multidose | Cyclosporine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Metolazone | Metolazone | 24 | 11 |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Procrit | Epoetin Alfa | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 19 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tacrolimus | Tacrolimus | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 11 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Tolvaptan | Tolvaptan | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.57 · 4 records | AERIN MEDICAL INC. | OTEZLA, POCKET EEG DEVICE, REPATHA, RHINAER STYLUS, VIVAER STYLUS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error